![]()

Key Takeaways
- More than half of pharmaceutical launches fail to meet expectations, with that figure climbing even higher in competitive therapeutic areas.
- Clinical trials run on selected populations and strict protocols that rarely reflect everyday comorbidities, prescribing habits or how patients actually move through care.
- Longitudinal claims data can reveal treatment switches, persistence, hospitalisations and the gaps where patients go untreated altogether.
- Segmenting patients by severity, comorbidities and treatment status turns a rough prevalence estimate into a realistic, addressable population size.
- Starting claims-data analysis as early as Phase III, and revisiting it as payer policy shifts, is one way launch teams keep their assumptions honest.
Launching a new medicine is a high-stakes undertaking, and even a promising therapy can struggle when commercial forecasts fail to match real-world patient needs. Clinical trial findings provide essential evidence, but they cannot always explain how patients move through routine care, why treatments are discontinued, or which barriers affect access.
According to MEDDDICAL, which advises pharmaceutical and MedTech organizations on real-world evidence strategies, one of the most important decisions in launch planning is identifying which patient data can reliably answer the commercial questions at hand. The firm’s advisory perspective emphasizes testing market assumptions against observed treatment patterns, patient populations, and healthcare utilization before committing resources to a launch.
Understanding where those assumptions fall short can help launch teams improve demand forecasts, identify treatment gaps, and prepare more effectively for market access requirements.
Why Over Half of Launches Underperform
More than half of all product launches fail to meet expectations, and in competitive therapeutic areas that failure rate climbs even higher. The usual culprit is not a lack of ambition or a weak product profile. It is a planning process built on clinical trial extrapolations and market assumptions rather than evidence of how patients actually move through diagnosis, treatment and care.
This matters more than ever in tightly regulated markets, where health technology assessment bodies expect thorough real-world evidence and reimbursement authorities want proof of added therapeutic benefit.
The forecasting errors that sink launches tend to follow a pattern: overestimating how many patients are eligible and accessible, underestimating payer friction, and assuming uptake will follow a textbook curve. A forecast built this way looks tidy on a slide, but it rarely survives contact with an actual healthcare system, actual prescriber habits and actual payer scrutiny.
Clinical Trials Don’t Mirror Real Practice
Clinical trials are designed to answer a narrow, controlled question: does this medicine work under carefully managed conditions? They are excellent at proving efficacy. They are far less reliable as a guide to how a medicine will perform once it reaches ordinary clinics, pharmacies and patients juggling several health conditions at once.
Selected Populations, Strict Protocols
Phase III trials typically enrol patients chosen for how well they fit a specific profile, often excluding the comorbidities and complications that are common in everyday practice. Strict protocols dictate dosing, monitoring and follow-up in ways that rarely match how busy clinicians actually prescribe. When a launch forecast rests mainly on these extrapolations, the plan effectively bets on a best-case scenario that may never occur outside the trial setting.
The consequence shows up quickly once pricing negotiations begin. Many health systems expect manufacturers to demonstrate added therapeutic benefit within the first year of launch, and a dossier built only on trial data can struggle to answer the practical questions payers ask: how does this medicine perform against what patients are already receiving, and how many patients genuinely stand to benefit?
Mapping the Real Patient Pathway
Understanding the real patient pathway means tracing what happens from first symptom to diagnosis, through treatment initiation, switches, persistence and, eventually, either stabilisation or relapse. Claims data, laboratory results and clinical pathway information together build a picture that no single trial could ever capture, because they reflect millions of actual decisions made by actual clinicians and patients.
Spotting Friction in Diagnosis and Access
Patient pathway analysis can identify exactly where friction builds up in diagnosis, treatment access and therapy initiation. Claims and medical records help locate these pressure points within existing pathways, whether that is a delay in referral to a specialist, a diagnostic test that is hard to access, or a prescribing restriction that quietly blocks uptake. Spotting these friction points early lets a launch team design messaging and support programmes that target the actual barrier, rather than guessing at one.
A practical way to apply this is piloting the patient pathway mapping in one or two countries before expanding further, then refining the approach using feedback gathered along the way. This keeps the exercise manageable and lets a team validate assumptions before committing to a full rollout.
Treatment Switches, Persistence and Gaps
Longitudinal claims data can show treatment sequences, therapy switches, prescription persistence, hospitalisations and the periods when patients go untreated entirely. These patterns reveal far more than a simple prevalence number ever could. A launch team preparing to enter a chronic disease area, for example, can see the typical progression from first-line therapy through dual therapy and beyond, including how long patients typically spend at each stage and where the drop-offs happen.
These gap periods, where a diagnosed patient simply stops receiving treatment, are often where the clearest opportunity sits. A medicine that addresses tolerability, convenience or a persistence problem visible in the data has a far stronger, more credible launch story than one built purely on a trial endpoint.
Sizing the True Addressable Population
Getting the market size right is one of the most consequential steps in launch planning, and one of the easiest to get wrong. The standard approach of applying trial prevalence estimates to census figures, then layering on optimistic assumptions about diagnosis and treatment-seeking behaviour, tends to produce numbers that look reassuring and perform poorly.
Segmenting Patients by Severity and Status
Claims-based patient counts can be segmented by factors such as severity, comorbidities, age, geography and current treatment status. This segmentation turns a blunt epidemiological estimate into something closer to a precise forecast of who is actually eligible for, and likely to receive, a new therapy. It also helps answer practical questions a launch team needs before committing resources:
- How many patients are currently diagnosed with the target condition, and how does that vary by region?
- Which patient segments appear undertreated or are still using older therapies?
- What proportion carry the comorbidity profile studied in the clinical programme?
- Where are the geographic concentrations of patients and specialist centres?
Finding Unmet Needs and Treatment Gaps
Treatment gaps can include early discontinuation, delayed intensification and diagnosed patients who never receive guideline-recommended therapy. Each of these gaps tells a different story about why current care is falling short, and each points to a different kind of launch opportunity. High discontinuation within the first few months of a therapy, for instance, suggests a tolerability or convenience problem. Patients lingering on a failing regimen for too long before any change is made points to clinical inertia, which a well-positioned new option might help resolve.
Claims data can also help teams examine healthcare use, hospitalisations, outpatient visits and the costs associated with different patient characteristics and treatment statuses. This burden-of-illness picture becomes essential later, when building the evidence base for payer conversations.
Forecasting Uptake With Confidence
A forecast is only as strong as the assumptions behind it. Forecasts built on generic adoption curves and best-case thinking tend to overstate how many patients will realistically access a new medicine, and understate the friction payers introduce along the way. Making assumptions explicit, and testing them against country-specific treatment patterns, produces forecasts that hold up under scrutiny.
Learning From Analog Launches
Analog launches, meaning earlier medicines with a similar mechanism, indication or positioning, can inform uptake forecasts in ways that generic models cannot. Country-specific health technology assessment timing, reimbursement processes and rollout patterns also matter enormously, so an analog from one market will not automatically translate to another. The value lies in combining analog learning with local market nuance rather than treating a single historical curve as a universal template.
Tracking Competitors and Prescriber Patterns
Launch teams can use claims data to track competitors’ market share, treatment-line positioning, prescriber patterns and regional variation over time. This kind of ongoing tracking answers questions that static competitive intelligence reports miss:
- Which specialties adopted a competing therapy quickly, and which stayed cautious?
- Where does a competing product typically sit in the treatment sequence, first-line or reserved for later failures?
- Which regions show distinctly different prescribing patterns, and why?
This kind of analysis helps a launch team position a new medicine realistically, rather than assuming it will simply slot into whatever gap looks most attractive on paper.
Winning Payer and Market Access
Payers rarely accept a value story built entirely on trial efficacy. They want to understand how a new medicine performs against what patients are actually receiving today, and how large the affected population genuinely is within their own health system.
Where Claims Data Complements Trial Evidence
Claims data can support payer and health technology assessment evidence on disease burden and treatment patterns, complementing rather than replacing clinical trial evidence. It is worth being clear about the limits here: claims data alone may not capture clinical details such as disease severity, biomarker status or patient-reported outcomes, so complementary sources are often needed to round out the picture. A launch team can also draw on historical market-access data and analogous products to investigate coverage restrictions and likely launch trajectory, supplementing that analysis with direct conversations with payers to test how assumptions hold up in practice.
This combination, trial evidence for efficacy and claims-based evidence for real-world burden and treatment gaps, tends to produce a far more persuasive dossier than either source could create alone.
Starting Early and Validating Often
The strongest launch plans treat claims-data analysis as a phased process rather than a last-minute checklist. Beginning the work during Phase III, well before launch, allows a team to validate assumptions, refine the target product profile and shape evidence generation strategy while there is still time to act on what the data reveals.
Markets do not stand still after launch. Guidelines change, new competitors enter, and payer policy shifts in ways that can quietly undermine an otherwise solid plan. Comparing payer readiness against original assumptions at a planned review point helps a team avoid two common failure modes: overreacting to early noise, or ignoring a genuine signal that the plan needs adjusting.
Reliable Launches Demand Real-World Proof
Clinical trials remain essential for proving a medicine works. They were never designed to predict how it will perform once it meets the full complexity of real clinical practice, varied payer systems and patients managing several conditions at once. Mapping the real patient pathway, sizing the addressable population with genuine precision, forecasting uptake against credible analogs and building a payer case grounded in real-world evidence together turn launch planning from an exercise in hope into one built on evidence.
Before finalizing a launch strategy, teams should review their most uncertain assumptions and determine which data sources can help validate them. MEDDDICAL’s website provides further information on evaluating real-world evidence requirements and identifying suitable health insurance data partners for pharmaceutical launch planning.
MEDDDICAL
Aptos 221
Edificio D2C
Sotogrande
Cadiz
11310
Spain

